Histogen Inc. (HSTO)


-0.01 (-3.13%)
Symbol HSTO
Price $0.31
Beta 1.154
Volume Avg. 0.27M
Market Cap 1.324M
Shares () -
52 Week Range 0.3-1.62
1y Target Est -
DCF Unlevered HSTO DCF ->
DCF Levered HSTO LDCF ->
ROE -122.56% Strong Sell
ROA -213.27% Strong Sell
Operating Margin -
Debt / Equity -
P/E -0.11 Neutral
P/B 0.24 Neutral


Consensus EPS

Upgrades & Downgrades

Latest HSTO news

Ms. Susan A. Knudson
NASDAQ Capital Market

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.